Welcome! Follow along!



"I'm so glad you're here:"

Harm reduction wound care for xylazine and injection related wounds in lowbarrier and street-based settings

> AMERSA Workshop Session November 3, 2023



Presenters



Rebecca Hosey, MPH, BSN, RN



Raagini Jawa, MD, MPH, FASAM



Rachel McFadden, MPH, BSN, RN, CERN



Rachel Neuschatz, MSN, RN



Ashish Thakrar, MD, FASAM

Follow along!



Funding and Disclosures

- No presenters have anything to disclose.
- Raagini Jawa receives funding from NIDA; K12DA050607-03.
- **Disclaimer**: We do not endorse any specific products or brands or receive financial support from any of the brands or products mentioned. We often use least expensive options available, or donated goods.

Workshop Outline

Intro: Brief introduction to xylazine and current U.S. epidemiology

Part 1: Review assessment & treatment strategies for xylazine-associated wounds

Part 2: Identify barriers & solutions to continuity of care for wounds

Part 3: Discuss important features of low-barrier, harm reduction wound care

Intro to Xylazine

Hosey, McFadden, AMERSA, 2023

What is Xylazine?

- Alpha-2 adrenergic agonist
- Animal sedative
- Human trials halted due to bradycardia, hypotension, sedation
- Distinct wound/soft tissue injury from chronic exposure
- Scheduled at state-level, not by DEA



<u>Health</u>

Pennsylvania will classify xylazine as a schedule III drug, Gov. Shapiro announces

Xylazine, also known as tranq, is legal for veterinary use to sedate large animals. But in recent years, the drug has spread into fentanyl supplies across the country, including Philadelphia.



by Gillian McGoldrick and Ximena Conde Published Apr. 18, 2023, 11:58 a.m. ET | Updated 2:31 p.m. ET

Where is Xylazine?

Early 2000s, Puerto Rico

- 40% of collected syringes
- o Diverted from rural areas

2020, Philadelphia

- Oversedation & distinct wounds reported by people who use drugs
- Medical examiner testing in overdose cases
- City commences testing of illicit supply
- >90% illicit fentanyl containing xylazine
- o Ratio highly variable

Hosey, McFadden, AMERSA, 2023

> Inj Prev. 2021 Aug;27(4):395-398. doi: 10.1136/injuryprev-2020-043968. Epub 2021 Feb 3.

Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019


Jewell Johnson ¹, Lia Pizzicato ², Caroline Johnson ², Kendra Viner ²

"Dope" samples containing Xylazine, Philly		
2021 Q1	100%	
2021 Q2	95%	
2021 Q3	89%	
2021 Q4	94%	
2022 Q1	97%	
2022 Q2	98%	
2022 Q3	91%	

Johnson, J, 2021 npsdiscovery.org/category/drug-checking/

Hosey, McFadden, AMERSA, 2023

2023: Xylazine Across the U.S.



Photos used with patients' written consent.

Wound Typology

Necrotic vs infectious in nature

- Unlike traditional injection-related wounds are infectious cellulitis, abscess
- Xylazine wounds start with soft tissue necrosis
- Progress to full-thickness *ulcerations*, may reach deeper structures (bone, tendon)
- =PAIN

May develop AT or AWAY FROM sites of injection

- 1. AT (photos): Start as purple irregularly shaped blisters
 - Develop adherent eschar
 - Expansion of necrosis & ulceration
- 2. AWAY FROM: Coin-size ulcerations, friable "cap" of devitalized tissue

May develop in the setting other modes of drug consumption (e.g. smoking, snorting)



Hosey, McFadden, AMERSA, 2023

Wound Assessment & Treatment

DIME: Keys to Healing

- **D: Debridement** | Remove necrotic tissue
- **I: Infection** | Assess for & treat
- M: Moisture | Balanced moisture
- **E: Edges** | Protect intact peri-wound tissue

DIME | Debridement

Non-viable or necrotic tissue is bad

Prevents epithelialization, revascularization Increases bioburden, risk of superimposed infection

- Eschar: Hard, dark, adherent
- **Slough:** Softer, yellow, adherent or mucinous

Get rid of it! Help "reset" natural healing

- 1. <u>Autolytic</u>: Topicals to encourages body's natural capacity
 - Medical grade honey, Hydrogel, PHMB
- 2. <u>Enzymatic</u>: Collagenase topical, dissolves necrotic tissue • Santyl
 - Surgical/Sharps: Phys
- 3. <u>Surgical/Sharps:</u> Physical removal
 - Secondary care setting (hospital, wound clinic)

McFadden, Hosey, AMERSA, 2023



Photo credit: Vazeille et al. Cureus. 2020 12(6)

DIME | Infection

Classic signs

- Periwound erythema, swelling, increased pain
- o Malodorous, purulent drainage

Biofilm "Gloss"

- Colonization of pathogenic or non-pathogenic bacteria; reproduce & disperse
- Pro-inflammatory state inhibits healing


MRSA + Strep A

- ~24% cases of infective endocarditis linked to IDU
- Implications for topical & systemic abx choice
 McFadden, Hosey, AMERSA, 2023



Photo credit: Coloplast alenciano et al. <u>Clin Infec Dis</u>. 2021 73(11) McCarthy et al. <u>Clin Infect Dis</u>. 2020 71(7) Jackson et al. <u>MMWR Weekly</u>. 2018 67(22)

Spectrum of Injection-related Infections



Antibiotic Treatment Consideration

Signs and Symptoms	Non-purulent	Purulent	Necrotizing Fasciitis
Mild	Cephalexin 500mg q6h OR Cefadroxil 500mg q12	Doxycycline 100mg BID	Inpatient Surgical Eval
	Bactrim 2DS BID	OR	<u>AND</u>
	(beta-lactam allergy)	Bactrim 2DS BID	IV ANTIBIOTICS!

Jawa, AMERSA, 2023

DIME | Moisture & Edges

Moisture Balance

- Add to dry wounds (e.g. hydrogel)
- Absorb from wet wounds (e.g. alginate dressings absorb 15-20x their weight)

Edges & Environment

- Protect the peri-wound tissue
 - Petroleum-based ointment (e.g. A&D), barrier cream
 - Discuss injection site alternatives
 - Review safer infection practices
 - Address picking less is best, hand sani or gloves
- Protective dressing, especially if rough sleeping

McFadden, Hosey, AMERSA, 2023



Photo credit: Shutterstock

Basic Dressing Change

1 Prep materials

Minimize wound exposure time

- 2 Remove old Patient can do this!
- 3 Cleanse Spot test new products

4 Topicals & Ointments Wound & edges

- 5 Primary dressing Non-stick
- 6 Secondary dressing Absorbent

Securement

McFadden, Hosey, AMERSA, 2023

Potable Water

Bottled or tap



Normal Saline

3 | Cleansers

Well-tolerated "Bullets" for take-home kits

Mild soap





Vashe

Hypochlorous acid: Weak acid, strong antimicrobial

Supports debridement



Di-Dak-Sol 0.125%

Diluted Dakins/hypochlorite solution Non-cytotoxic, broad-spectrum antimicrobial *CAUTION*: Much stronger formulations also exist!

NO alcohol or peroxide!!

4 | Ointments & Topicals

A+D \$

Protective **barrier** Apply to & around wound Petrolatum & lanolin





Zinc-based \$

Anti-inflammatory Apply to & around wound **Thicker** than A&D

Antibiotic \$-\$\$

Reduce bioburden OTC Bacitracin RX Mupirocin Be judicious!



McFadden, Hosey, AMERSA, 2023

4 | Ointments & Topicals

Autolytic Debridement \$\$

Medihoney Medical grade Anti-inflammatory *Prevents* bacteria growth Consider: Hot weather & insects

NON-antimicrobial

Hydrogel Add moisture



PHMB

HEXAGEN

Non-cytotoxic Base determines debridement (gel >> petroleum) Broad-spectrum antimicrobial

Silver Products

SIL VASORB® GEL

Non-cytotoxic in short/med term Gel base better for debridement Broad-spectrum antimicrobial

Strong antimicrobial

Enzymatic Debridement \$\$\$

Collagenase (Santyl)

Will not penetrate thick eschar (1st soften with autolytic agent) Do not mix with silver products



Hosey, McFadden, AMERSA, 2023

McFadden, Hosey, AMERSA, 2023

5|Primary

Non-stick is key Closest to wound



Oil-Emulsion: Wet wound

6|Secondary

Absorptive

If saturated, can change while leaving Primary dressing intact

Non-adherent pads, ABD pads, Woven gauze, Roll gauze 7|Secure

Consider environment

When will the next dressing change be?

Coban, ACE bandage, Tubigrip Socks, shoes, gloves!



Petroleum-based: Dry wounds





Breakout: Applying DIME

Each person has a different supply at their seat.

Work with your group and leader to apply the DIME method to the photo of the wound provided.

Feel free to practice on a groupmate.

Continuity of Care

Need for Higher Level of Care

When does a xylazine-associated wound require treatment escalation?

- Signs of systemic infection: Fever, nausea, confusion that *not* explained by withdrawal/intoxication
- Local infection in high-risk area: Hand, joint, groin, neck
- Local infection not improving with oral antibiotics
- Large area of non-viable tissue requiring evaluation for surgical debridement
- Exposure of deeper structures: Bone, tendon, muscle
- Loss of function: Weakness, decreased sensation

May be a series of conversations!

Person may initially decline – but continue to discuss

- Explain rationale, concerns
- Get to know their fears & barriers
- Explore solutions

Warm Hand-off

Partnership between community-based & higher level of care

Protocolize a referral system

- Who's involved, responsibilities, expectations
- Creates accountability

Bi-directional! Don't miss hand-off back to community

- Secure chat groups
- Patient registry
- Shared repository of resources




Make a Plan Talk through EACH step

- . Secure belongings
- . "Get well" before leaving
- . Transportation
- . Which hospital?
- . Best time of day/night?
- "Buddy system" or escort
- . Goals: Interested in MOUD?



Thakrar, McFadden, Jawa, AMERSA, 2023



Inpatient Addiction Care

Delivers evidence-based SUD care during hospitalization

Guides withdrawal management, initiation of medications to stabilize SUD

MANY potential benefits!

- Improve quality of care experienced by people who use drugs (PWUD)
- Decreasing self-directed discharges and utilization costs
- Culture change to reduce stigma towards people with SUD in health institutions by improving staff education/sensitivity

Weinstein et al. Med Clin North Am. 2018 102(4)

Benefits of Inpatient Addiction Care

Opioid Withdrawal & Pain Management

- Illicit fentanyl = HIGH opioid tolerance, hyperalgesia
- <u>Novel Approach</u>: Short + Long-acting full-agonists
 - Scheduled, not PRN
 - Cross-taper with MOUD
 - Maintain tolerance/reduce overdose risk if no MOUD

Polysubstance use

• **Common & can be complicated!** Xylazine, cocaine, benzodiazepines, alcohol, methamphetamine, etc.

Wrap-around Services

- Peer Recovery Specialists: Peer support, engagement
- Social Workers: Placement, social determinants

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder

Ashish P. Thakrar ⊠, Tanya J. Uritsky, Cara Christopher, Anna Winston, Kaitlin Ronning, Anna Lee Sigueza, Anne Caputo, Rachel McFadden, Jennifer M. Olenik, Jeanmarie Perrone, M. Kit Delgado, Margaret Lowenstein & Peggy Compton

Addiction Science & Clinical Practice 18, Article number: 13 (2023) Cite this article

Initial Management of Withdrawal and Pain in Hospitalized Patients with Opioid Use Disorder (OUD) Using Fentanyl

- Patients using ≥3 bags of fentanyl daily: use this approach with these doses, even if patient received higher doses during a recent hospitalization.
- Patients using <2 bags fentanyl or who have critical illness, older age, frailty, or significant renal/hepatic impairment: reduce doses by 50%.

1. Assess & Diagnose OUD

- Diagnose OUD using DSM-5 criteria & document current substance using DSM-5 criteria
- Ask patient about goals and history of treatment: medications, psych
- Obtain urine drug test when feasible; do not wait for results to initiat
 Many patients have overlapping withdrawal and pain. Partne

regimen that aligns patient goals for comfort with our respon

2. Stabilize & Engage

Continue outpatient OUD treatment: if stable on methadone/buprenorp call opioid treatment program for methadone) and continue home dose if

Start a long-acting opioid (methadone or buprenorphine preferred) whi



What Makes Inpatient Addiction Care Work?

Essential Program Elements

Clinical Champions	Enthusiastic, "early adopters" who serve as local resources
Education & Culture	Leverage education, communication, & events to promote a visible commitment to high-quality addiction care
Policies	Build interprofessional support for harm reduction-oriented policies (e.g. response to in-hospital illicit substance use)
Incentives & Metrics	Align metrics & financial incentives with SUD best practices to sustain high quality care

Englander, et al. (Under Review)

What Makes Inpatient Addiction Care Work?

Essential Patient Care Elements

Reachability	Centralized contact method for teams to seek support
Contingency Plans	Acknowledge the reality of care plan changes, and develop harm reduction-oriented responses
Social Supports System	Engage family, friends, community case/social workers as much as possible, with consent
Community Resources	Coordinated, timely referrals to relevant community programs

Effective addiction care can be delivered via many models

Be creative with the resources & champions you have in place!

Breakout:

Put it all together with your group.

Discuss what care and supplies you would provide, barriers to care, person-centered needs, etc.

Write down 2-3 stand out pearls or challenges to share with the entire group







Ehrman- Dupre, Kaigh, et al, JAM, 2022.

Carlos



Photos used with patients' written consent.

Photos used with patients' written consent.



Low-to-No Barrier Care Provision

Harm Reduction in Clinical Care

Related frameworks:

Trauma-informed Person-centered Informed consent Strengths-based



Relationships > Results Mutual respect Nonjudgmental curiosity "In your corner"


Neuschatz, Hosey, AMERSA, 2023


Reduce Barriers, Reduce Harm: Street Medicine

- Street Medicine Movement to bring health care to the unhoused, since the 1990s
 - Programs expanding nationally and globally, responding to need
 - Upstream care—reach people before they show up in the ED
- Continue trajectory of increasing community- and home-based services
 - Increased focus on patient factors and impact of environment
 - Less is within clinician (and sometimes also patient) control
- High co-occurrence of substance use disorder and housing instability

Neuschatz, Hosey, AMERSA, 2023

Spectrum of Low Barrier Community Services





Treating People on Their Own Terms

- Care without an exam room: evolving comfort zones
 - Minimize assumptions—maximize individualized care
 - Privacy vs. accessibility with open-air care
- Ask preferences
- Accommodate, when possible
- Informed consents, apologies, and alternatives if possible
- Consideration of both patient and provider: finding overlap of safety



Photo credit: Galen Pugh

Neuschatz, Hosey, AMERSA, 2023

Neuschatz, Hosey, AMERSA, 2023

High Level View

- Partnerships
 - Cultural humility and competency
 - Rapport/relationship, trust/buy-in, safety and longevity
- Same space, different perceived needs
 - Concerns from all neighbors
- Passers-by
 - Positives and negatives
 - Flexibility and responsiveness




Street Level View



- Does it impact informed consent?
- Pain management in the field
- Overdose response
 - Appropriate response per level of training
 - Impact of xylazine: sometimes sedation > hypoxia
- Someone needs a higher level of care
 - Safety planning, informed consent, menu of options

https://www.mountainside-medical.com/products/manual-resuscitation-bag https://www.health.com/fitness/best-pulse-oximeter



Thank you.

We express our deep gratitude to the people we see in clinic, on the street, vans, cars, and by phone.

To our colleagues, lead nurses Kristi Petrillo-Straub, Sara Wallace-Keeshen, Keara McNulty, and fellow street nurse Stephanie Klipp; physicians Dr. Eyiah-Mensah, Dr. Healy, Dr. Romeo, Dr. Kaigh, Dr. Hart, Dr., Moore, and lead navigators, Rachel Winter, Neha Shetty, and the rest of the Wound Care Clinic team.

References

Bryant, R., & Nix, D. (2015). Acute and chronic wounds: current management concepts. Elsevier Health Sciences.

Ehrman-Dupre, R., Kaigh, C., Salzman, M., Haroz, L.-K., & Peterson, R. (2022). Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report. *Journal of Addiction Medicine.*, *16*(5), 595–598. <u>https://doi.org/10.1097/ADM.0000000000955</u>

Englander, H., Thakrar, A.P., Bagley, S.M., Rolley, T., Dong, K., & Hyshka, E. (2022). Caring for Hospitalized Adults with Opioid Use Disorder in the Era of Fentanyl: A Review. Presented at AMERSA National Conference.

Fyffe, JJ. (1994). Effects of xylazine on humans: a review. Australian Veterinary Journal., 71(9), 294–295. https://doi.org/10.1111/j.1751-0813.1994.tb03448.x

Johnson, J., Pizzicato, L., Johnson, C., & Viner, K. (2021). Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019. *Injury* prevention, 27(4), 395-398.

Malayala, S. V., Papudesi, B., Bobb, R., et al. (2022) Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA. Cureus 14(8): e28160. doi:10.7759/cureus.28160

Powers, J., Higham, C., Broussard, K., & Phillips, T. J. (2016). Wound healing and treating wounds. *Journal of the American Academy of Dermatology.*, 74(4), 607–625. https://doi.org/10.1016/j.jaad.2015.08.070

Reed, M. K., Imperato, N. S., Bowles, J. M., Salcedo, V. J., Guth, A., & Rising, K. L. (2022). Perspectives of people in Philadelphia who use fentanyl/heroin adulterated with the animal tranquilizer xylazine; Making a case for xylazine test strips. *Drug and alcohol dependence reports*, *4*, 100074.

Roux, P., Jauffret-Roustide, M., Donadille, C., Briand Madrid, L., Denis, C., Célérier, I., Chauvin, C., Hamelin, N., Maradan, G., Carrieri, M.P., Protopopescu, C., Lalanne, L., Auriacombe, M., Berenger, C., Bertoia, G., (2022). Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. *International Journal of Epidemiology*. <u>https://doi.org/10.1093/ije/dyac120</u>

Torruella, R. A. (2011). Xylazine (veterinary sedative) use in Puerto Rico. SubstanceAbuse Treatment, Prevention, and Policy, 6, 1-4.

Vazeille, S., Hawker, L., Chandrasekar, R., & Srinivas-Shankar, U. (2020). Recalcitrant Foot Ulceration in a Patient With Type 1 Diabetes Mellitus. *Cureus*, *12*(6), e8898. https://doi.org/10.7759/cureus.8898

Harm Reduction Applied: Maximizing Self Management

Establish Rapport

Many people have been treated disrespectfully by others in health care

Authenticity—as a person and provider—builds trust

Bodily Autonomy

Explain before doing, ask before touching Be responsive in words and action to reports of pain, etc.

Strengths Focused

Reflect what's positive about wound progression or self care, if at all possible Acknowledge small steps, including presenting for wound care

Offer Tools for Desired Outcome

Explain clinical assessment and decision making

Offer rationales so substitutes can be more effective

Provide supplies for dressing changes prior to next visit